{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:26:49Z","timestamp":1788672409599,"version":"build-2803163510"},"reference-count":38,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7236-26","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:09:47Z","timestamp":1779487787000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Switching from oral to Subcutaneous Methotrexate in Alleviating Methotrexate-related Intolerance Symptoms in Japanese Patients with Rheumatoid Arthritis: The METOJECTIVE Study"],"prefix":"10.2169","author":[{"given":"Shin-ichiro","family":"Ohmura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Yukishima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Fukami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"},{"name":"Miyamoto Internal Medicine\/ Rheumatology Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79: 685-699, 2020."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kawahito Y, Morinobu A, Kaneko Y, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication. Mod Rheumatol 33: 21-35, 2023.","DOI":"10.1093\/mr\/roac017"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dubey L, Chatterjee S, Ghosh A. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study. Indian J Pharmacol 48: 591-594, 2016.","DOI":"10.4103\/0253-7613.190761"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 41: 293-299, 2014.","DOI":"10.3899\/jrheum.130270"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 23: 955-967, 1997.","DOI":"10.1016\/S0889-857X(05)70368-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24: 411-421, 1995.","DOI":"10.1016\/S0049-0172(95)80009-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Clerc D, Brousse C, Mariette X, Bennet P, Bisson M. Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone. Ann Rheum Dis 50: 67, 1991.","DOI":"10.1136\/ard.50.1.67-b"},{"key":"8","unstructured":"8. Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 18: 1172-1175, 1991."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 150: 258-260, 1994.","DOI":"10.1164\/ajrccm.150.1.8025760"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ohmura SI, Homma Y, Masui T, Miyamoto T. Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study. Intern Med 61: 997-1006, 2022.","DOI":"10.2169\/internalmedicine.8205-21"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Atsumi T, Tanaka Y, Yamamoto K, et al. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis 76: 1348-1356, 2017.","DOI":"10.1136\/annrheumdis-2016-210246"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dalkilic E, Sahbazlar M, Gullulu M, et al. The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Mod Rheumatol 23: 525-528, 2013.","DOI":"10.3109\/s10165-012-0685-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanaka Y. Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis. Mod Rheumatol 33: 633-639, 2023.","DOI":"10.1093\/mr\/roac156"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanaka Y, Okuda K, Takeuchi Y, et al. Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population. Mod Rheumatol 33: 680-689, 2023.","DOI":"10.1093\/mr\/roac103"},{"key":"15","unstructured":"15. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62: 2569-2581, 2010."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kameda H, Yamaoka K, Yamanishi Y, et al. Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication. Mod Rheumatol 34: 1-10, 2023.","DOI":"10.1093\/mr\/road098"},{"key":"17","unstructured":"17. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017 [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/ctep.cancer.gov\/"},{"key":"18","unstructured":"18. Metoject Subcutaneous Injection. 2023 [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/www.kegg.jp\/"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Meek R, Kelly AM, Hu XF. Use of the visual analog scale to rate and monitor severity of nausea in the emergency department. Acad Emerg Med 16: 1304-1310, 2009.","DOI":"10.1111\/j.1553-2712.2009.00581.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hendey GW, Donner NF, Fuller K. Clinically significant changes in nausea as measured on a visual analog scale. Ann Emerg Med 45: 77-81, 2005.","DOI":"10.1016\/j.annemergmed.2004.07.446"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"22","unstructured":"22. Islam MS, Haq SA, Islam MN, et al. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J 22: 483-488, 2013."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. Semin Arthritis Rheum 45: 656-662, 2016.","DOI":"10.1016\/j.semarthrit.2015.11.004"},{"key":"24","unstructured":"24. Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol 32: 563-571, 2014."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kromann CB, Lage-Hansen PR, Koefoed M, Jemec GB. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatolog Treat 26: 188-190, 2015.","DOI":"10.3109\/09546634.2014.927817"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 62: 857-864, 2010.","DOI":"10.1002\/acr.20132"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 64: 2814-2823, 2012.","DOI":"10.1002\/art.34543"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Dhaon P, Das SK, Srivastava R, Agarwal G, Asthana A. Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study. Int J Rheum Dis 21: 1010-1017, 2018.","DOI":"10.1111\/1756-185X.12910"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Braun J, K\u00e4stner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58: 73-81, 2008.","DOI":"10.1002\/art.23144"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kanda M, Sato M, Nagahata K, et al. Assessment of oral methotrexate intolerance in Japanese adult patients with rheumatoid arthritis. Int J Rheum Dis 27: e15029, 2024.","DOI":"10.1111\/1756-185X.15029"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Pope JE. Management of Fatigue in Rheumatoid Arthritis. RMD Open 6: e001084, 2020.","DOI":"10.1136\/rmdopen-2019-001084"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nowell WB, Karis E, Gavigan K, et al. Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower\u00ae Registry. Rheumatol Ther 9: 207-221, 2022.","DOI":"10.1007\/s40744-021-00398-6"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Fautrel B, Kirkham B, Pope JE, et al. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. J Clin Med 8: 1394, 2019.","DOI":"10.3390\/jcm8091394"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Naoum G, Markantonis SL, Fanerou E, et al. On the Association between Gastrointestinal Symptoms and Extragastric Manifestations. Gastroenterol Res Pract 2022: 8379579, 2022.","DOI":"10.1155\/2022\/8379579"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLoS One 14: e0221823, 2019.","DOI":"10.1371\/journal.pone.0221823"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73: 1549-1551, 2014.","DOI":"10.1136\/annrheumdis-2014-205228"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75: 1003-1008, 2016.","DOI":"10.1136\/annrheumdis-2014-206504"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Stamp LK, Barclay ML, O&apos;Donnell JL, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 38: 2540-2547, 2011.","DOI":"10.3899\/jrheum.110481"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7236-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:40:58Z","timestamp":1779507658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7236-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7236-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7236-26"}}